Sumis Partners Launches, Uniting Industry Leaders to Redefine Life Sciences Consulting
illi News/10301202

INCLINE VILLAGE, Nev. & BOSTON - illiNews -- Sumis Partners, Inc. announces its launch as a next-generation professional services platform designed to meet the evolving demands of the life sciences, healthcare, and public health sectors. The firm brings together a network of senior-led, specialized teams operating across geographies and disease areas, offering clients breadth, speed, and precision without the inefficiencies of traditional consulting models.

Rooted in three principles—senior-led execution, tailored engagements, and a focus on measurable outcomes—Sumis is purpose-built for biopharma and health organizations facing complex challenges and high-stakes decisions in a rapidly evolving environment. The firm offers services across the full product lifecycle, including new product planning, business development, market access, commercialization, evidence generation, health policy, and digital/AI transformation.

"Sumis is not a repackaged legacy firm or investor-led roll-up looking for growth metrics. It's a ground-up structure built by operators, advisors, and strategists who have led launches, built systems, and solved the kinds of problems our clients face every day, oriented around the success of our customers and their products," said Jennifer Hinkel, President of Sigla Sciences, a Sumis Partners Affiliate, and one of the Sumis Partners founders.

Within a lean model, Sumis deploys highly-specialized, expert-driven teams with transparent pricing, flexible project scoping, and a digital-native approach. The firm supports clients in North America, Europe, and global launch markets through integrated offerings that span strategy, analytics, medical affairs, commercial, and creative.

More on illi News

• Tomorrow's World Today Shines Bright with Four Telly Awards at the 46th Annual Telly Awards
• AbbVie Partners with Chicago Cubs on "Striking Out Cancer"
• Chicago: Mayor Brandon Johnson, City Officials, Lamar Johnson Collaborative, and 548 Development Attend Groundbreaking of Mixed-Use West Humboldt Park Development
• ILLINOIS TEAMSTERS DEMAND LAWMAKERS PREVENT CATASTROPHIC CUTS TO PUBLIC TRANSPORTATION
• 6 Love Sports and Eight Sleep Announce Partnership Miami Women's Padel League Rebranded as the Eight Sleep Miami Women's Padel League by 6 Love Sports

By combining capabilities, Sumis Partners is equipped to support clients of all sizes in navigating reimbursement complexity, scaling evidence generation, accelerating launch planning, and building policy-aligned access strategies—all with senior accountability and no junior handoffs.

"Sumis is a purpose-built alliance designed for modern biopharma and health tech challenges," said Dr. Cory Kidd, founder of Advient Advisors, a Sumis Partners Affiliate, and one of the Sumis Partners founders. "Sumis is about impact, not process. We work shoulder-to-shoulder with our clients to accelerate outcomes and remove barriers."

"Joining Sumis Partners amplifies Metli's mission to redefine public health consulting through innovation, creativity, and deep expertise in patient-centered solutions. Our combined strengths empower us to deliver unmatched value in health equity, real-world evidence, and AI-driven engagement, ultimately transforming how organizations achieve meaningful health outcomes globally. Sumis is grounded in the fact that we are here for the patient," said Dr. Taylor Hirschberg, CEO of Metli, a Sumis Partners Affiliate, and one of the Sumis Partners founders.

Affiliate Firms & Capabilities

Sigla Sciences specializes in data-driven, technology-enabled market access, health economics, and launch strategy for biopharma, diagnostics, and devices. Known for its work in oncology, rare disease, immunology, and CGTs, Sigla applies strategic foresight, scenario planning, and predictive analytics to help innovators navigate policy and access complexity for successful product launches. Learn more at siglasciences.com.

Metli combines health equity, global public health, and creative strategy with deep capabilities in qualitative research, epidemiology, patient-centered design, and AI-enabled stakeholder engagement. The firm excels in integrating patient-reported outcomes (PROs) and real-world evidence (RWE) to drive high-impact programs across disease areas, with expert depth in infectious disease, oncology, health equity, and population health. Where imagination sparks discovery. Learn more at metliconsulting.com.

More on illi News

• The TOBU RAILWAY X COFFEE PROJECT Supports Nikko Tourism and Fosters English Speaking Guides, Through November 27, 2026
• Al-Tabbaa & Hackett: Fixed Rates Improve For Savers
• Zeigler Auto Group Earns its 12th Chicago's Best & Brightest Companies To Work For® Award
• Non-Citizen NY Travelers Face Extra Scrutiny at Local Airports: Attorney Robert Tsigler Featured in Gothamist
• $400 Million Run Rate in 2025 for Global Telcom Leader as a Result of Definitive Fintech Acquisition, Fast-Tracking $1 Billion Growth Plan: IQSTEL Inc

Rapid Commercialization Partners (RCP) provides commercialization and launch support to clinical-stage biotechs, delivering executive-level fractional leadership across strategy, marketing, and operations. RCP emphasizes acceleration, discipline, and long-term value creation. Learn more at rcpbio.com.

Advient Advisors, founded by MIT Media Lab PhD Dr. Cory Kidd, delivers strategic AI consulting and organizational readiness programs for life sciences, healthcare, and other complex and highly-regulated industries. The firm blends technical depth with behavioral science to enable sustainable digital transformation. Learn more at advientadvisors.com.

Solem Global operates across the U.S. and Europe to drive global launch readiness, pricing, distribution, and commercialization strategy. With operational teams in Washington DC, Madrid, and Münster, Solem offers in-country execution to match its senior-level strategic depth. Learn more at solemglobal.com.

Presley Global Management offers executive-level guidance to life sciences companies navigating FDA-regulated markets, combining commercialization expertise with implementation pathways designed to de-risk U.S. entry and accelerate ROI.